Results 141 to 150 of about 72,257 (246)

Episodic disorders: channelopathies and beyond. [PDF]

open access: yes, 2015
Ptáček, Louis J
core   +1 more source

Evaluation of the Antifungal Properties of Azomethine‐Pyrazole Derivatives from a Structural Perspective

open access: yesChemistryOpen, EarlyView.
A series of azomethine‐pyrazole derivatives bearing a para‐substituted azo‐phenyl ring is straightforwardly prepared. The new compounds display an elevated antifungal activity against various Candida species and Cryptococcus neoformans strains. DFT and molecular docking calculations are used to determine possible routes of action through interactions ...
María Isabel Murillo   +8 more
wiley   +1 more source

Ivermectin as a promising therapeutic option for onchocerciasis-associated epilepsy. [PDF]

open access: yesEpilepsia Open
Manavi MA   +4 more
europepmc   +1 more source

Targeted Isolation of Coumarins From Sideritis Species Based on Antiviral Screening and Untargeted Metabolomics

open access: yesPhytochemical Analysis, EarlyView.
ABSTRACT Introduction The SARS‐CoV‐2 pandemic has revealed a deficiency in antiviral agents. Plants, traditionally used for respiratory infections, are valuable sources of antiviral compounds. Such a plant is the Sideritis L. taxa (mountain tea), traditionally used against cold and cough.
Ekaterina‐Michaela Tomou   +5 more
wiley   +1 more source

Spina bifida as a multifactorial birth defect: Risk factors and genetic underpinnings

open access: yesPediatric Discovery, EarlyView.
Abstract Spina bifida is a birth defect resulting from abnormal embryonic development of the neural tube. Though spina bifida is divided into several subtypes, myelomeningocele—the most severe form of spina bifida often associated with a markedly diminished quality of life—accounts for a significant portion of cases.
Ethan S. Wong   +13 more
wiley   +1 more source

Effectiveness and safety of perampanel for pediatric patients with epilepsy: A real‐world study from China

open access: yesPediatric Investigation, EarlyView.
The 50% responder rate and seizure freedom rate after 6 months of PER treatment during routine clinical care were 70.4% and 22.1%, respectively. The 50% responder rates for the 3 age‐based cohorts were 64.5% in infants and young children, 73.4% in children and 69.2% in adolescents, and the Seizure‐freedom rates were 16.1%, 23.7% and 25.6% respectively.
Xiaohui Wang   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy